HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

M. Nielsen Hobbs

Executive Editor, US Regulatory & Policy

Washington, DC

Nielsen has been covering the pharmaceutical industry most of his life, reporting on everything from ANDAs to Zika vaccines. He strongly believes that the user fee system needs to stop using Roman numerals. His favorite stories are ones that help readers understand the personalities and policies that dictate whether their regulatory strategy succeeds or fails. A regular contributor to the Pink Sheet podcast, he also creates infographics and editorial feature images for articles. Before joining Pink Sheet he worked for Congressional Quarterly. Nielsen frequently moderates webinars and panels at industry conferences, and enjoys discussing R2-D2 almost as much as he enjoys talking about 351(k).

Latest From M. Nielsen Hobbs

FDA Still Soliciting Applications For START Pilot As Deadline For Rare Disease Program Looms

Agency anticipated receiving more applications for the program, which aims to bring Operation Warp Speed-like response to investigational rare disease therapies, than it has so far, though a last-minute ‘flood’ is still expected. CBER and CDER are accepting requests through 1 March.

Rare Diseases Drug Review

Immortalizing Janet Woodcock

Offering a regulatory Mt. Rushmore to place the outgoing principal deputy commissioner in historical context.

Leadership FDA

Pink Sheet Podcast: State Of Generic Industry, US FDA In Second Trump Term, Foreign Inspections

Pink Sheet reporter and editors discuss the issues and concerns raised during a major generic industry conference, former Commissioner Gottlieb’s views on what a second Trump term would mean for FDA, and congressional hearings on foreign facility inspections and drug shortages.

Generic Drugs FDA

Blue Shield Of California’s Pharmacy Benefit Overhaul Could Still See Boost From Transparency Legislation

The payor’s multiyear plan to ditch the traditional PBM model and use multiple vendors has drawn a lot of skepticism from other actors in the health care system, but Blue Shield is hoping that it can help give policymakers some momentum, VP Lum tells the Pink Sheet.

Interviews PBMs

‘We Did Too Good Of A Job’ On Lowering Prices: Sandoz’s Haruvi Discusses Generic Sustainability

As Hatch-Waxman celebrates its 40th anniversary, the chair of the US generic trade association talks about striking the right balance on supply and pricing, preventing shortages, and improving Medicare price negotiations.

Generic Drugs Biosimilars

Immortalizing Janet Woodcock

Offering a regulatory Mt. Rushmore to place the outgoing principal deputy commissioner in historical context.

Leadership FDA
See All
UsernamePublicRestriction

Register